In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma

Por Urosevic-Maiwald, Mirjana, Barysch, Marjam J, Cheng, Phil F, Karpova, Maria B, Steinert, Hans, Okoniewski, Michal J, Dummer, Reinhard
Publicado no Oncoimmunology (2015)

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

Por Raaijmakers, Marieke I. G., Widmer, Daniel S., Narechania, Apurva, Eichhoff, Ossia, Freiberger, Sandra N., Wenzina, Judith, Cheng, Phil F., Mihic-Probst, Daniela, Desalle, Rob, Dummer, Reinhard, Levesque, Mitchell P.
Publicado no Oncotarget (2016)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma

Por Cheng, Phil F, Shakhova, Olga, Widmer, Daniel S, Eichhoff, Ossia M, Zingg, Daniel, Frommel, Sandra C, Belloni, Benedetta, Raaijmakers, Marieke IG, Goldinger, Simone M, Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard, Levesque, Mitchell P
Publicado no Genome Biol (2015)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Por Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kähler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard, Goldinger, Simone M.
Publicado no PLoS One (2015)